Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Foresees JD HEALTH, ALI HEALTH to Achieve Double-Digit Rev. Growth Next Yr
Recommend 4 Positive 3 Negative 1 |
||||
|
||||
|
CLSA published a research report, covering JD HEALTH (06618.HK) and ALI HEALTH (00241.HK), which tracked strong 3Q25 results. Given the trade-in base effect, CLSA projected the 4Q25 guidance for these two companies to be conservative. However, they hold a positive outlook for next year's growth in pharmaceutical sales and margin expansion. CLSA forecast that the revenue of these two companies will manifest double-digit growth next year, with JD Health growing at a faster pace. The broker trimmed the target price of Alibaba Health from HK$6.5 to HK$6 to factor in the slower third-party GMV and revenue growth outlook, while the target price for JD Health was set at HK$71. Both companies were maintained at Outperform. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
